Role of chitinase 3-like-1 and semaphorin 7a in pulmonary melanoma metastasis

Cancer Research

Volumn 75, Issue 3, 2015, Pages 487-496

  Ma, Bing ^a   Herzog, Erica L ^b   Lee, Chun Geun ^a   Peng, Xueyan ^b   Lee, Chang Min ^a   Chen, Xiaosong ^b   Rockwell, Sara ^c   Koo, Ja Seok ^c   Kluger, Harriet ^c   Herbst, Roy S ^c   Sznol, Mario ^c   Elias, Jack A ^a,b  

^a BROWN UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; CHITINASE; CHITINASE 3 LIKE 1; COFILIN; LIM KINASE; PLEXIN; SEMAPHORIN; SEMAPHORIN 7A; UNCLASSIFIED DRUG; CHITINASE 3-LIKE 1, MOUSE; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; SEMA7A PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CONTROLLED STUDY; GENE DELETION; HUMAN; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LUNG METASTASIS; MELANOMA; MELANOMA CELL LINE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; REGULATORY MECHANISM; TUMOR MICROENVIRONMENT; ANIMAL; C57BL MOUSE; EXPERIMENTAL MELANOMA; GENE EXPRESSION REGULATION; GENE SILENCING; LUNG TUMOR; METABOLISM; PATHOLOGY; SECONDARY; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD; CELL LINE, TUMOR; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GLYCOPROTEINS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; SEMAPHORINS;

EID: 84961287947     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-3339     Document Type: Article

References (49)

1. Funkhouser JD, Aronson NN. Chitinase family GH18: evolutionary insights from the genomic history of a diverse protein family. BMC Evol Biol 2007;7:96.
2. Aerts JM, van Breemen MJ, Bussink AP, Ghauharali K, Sprenger R, Boot RG, et al. Biomarkers for lysosomal storage disorders: identification and application as exemplified by chitotriosidase in Gaucher disease. Acta Paediatr Suppl 2008;97:7-14.
3. Morrison BW, Leder P. neu and ras initiate murine mammary tumors that share genetic markers generally absent in c-myc and int-2-initiated tumors. Oncogene 1994;9:3417-26.
4. Lee CG Chitin, chitinases and chitinase-like proteins in allergic inflammation and tissue remodeling. Yonsei Med J 2009;50:22-30.
5. Lee CG, Da Silva CA, Dela Cruz CS, Ahangari F, Ma B, Kang MJ, et al. Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling and injury. Annu Rev Physiol 2011;73:479-501.
6. Lee CG, Elias JA. Role of breast regression protein-39/YKL-40 in asthma and allergic responses. Allergy Asthma Immunol Res 2010;2:20-7.
7. Lee CG, Hartl D, Lee GR, Koller B, Matsuura H, Da Silva CA, et al. Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis. J Exp Med 2009;206:1149-66.
8. Dela Cruz CS, Liu W, He CH, Jacoby A, Gornitsky A, Ma B, et al. Chitinase 3-like-1 (Chi3l1) Regulation of Streptococcus pneumoniae Lung Infection. Cell Host Microbe 2012;12:34-46.
9. Johansen JS, Jensen HS, Price PA. A new biochemical marker for joint injury. Analysis of YKL-40 in serum and synovial fluid. Br J Rheumatol 1993;32:949-55.
10. Choi IK, Kim YH, Kim JS, Seo JH. High serum YKL-40 is a poor prognostic marker in patients with advanced non-small cell lung cancer. Act Oncol 2010;49:861-4.
11. Johansen JS, Schultz NA, Jensen BV. Plasma YKL-40: a potential new cancer biomarker? Future Oncol 2009;5:1065-82.
12. Johansen JS, Cintin C, Jorgensen M, Kamby C, Price PA. Serum YKL-40: a new potential marker of prognosis and location of metastases of patients with recurrent breast cancer. Eur J Cancer 1995;31A:1437-42.
13. Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev 2006;15:194-202.
14. Iwamoto FM, Hottinger AF, Karimi S, Riedel E, Dantis J, Jahdi M, et al. Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. Neuro Oncol 2011;13:1244-51.
15. He CH, Lee CG, Dela Cruz CS, Lee CM, Zhou Y, Ahangari F, et al. Chitinase 3-like-1 binds to, signals and regulates cellular and tissue responses via IL-13 receptor α2. Cell Rep 2013;4:830-41.
16. Fujisawa T, Joshi BH, Puri RK. IL-13 regulates cancer invasion and metastasis through IL-13Ralpha2 via ERK/AP-1 pathway in mouse model of human ovarian cancer. Int J Cancer 2012;131:344-56.
17. Barderas R, Bartolome RA, Fernandez-Acenero MJ, Torres S, Casal JI. High expression of IL-13 receptor alpha2 in colorectal cancer is associated with invasion, liver metastasis, and poor prognosis. Cancer Res 2012;72:2780-90.
18. Fichtner-Feigl S, Strober S, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13alpha(2) receptor is involved in induction of TGF-beta(1) production and fibrosis. Nat Med 2006;12:99-106.
19. Yang JS, Allahverdian S, Singhera GK, MacRedmond RE, Dorscheid DR. IL-13Ralpha2/AP-1 complex signalling mediates airway epithelial repair without effects on remodeling pathways. Allergy Asthma Clin Immunol 2010;6:P27-P28.
20. Strober W, Kitani A, Fichtner-Feigl S, Fuss IJ. The signaling function of the IL-13Ralpha2 receptor in the development of gastrointestinal fibrosis and cancer surveillance. Curr Mol Med 2009;9:740-50.
21. Zheng T, Liu W, Oh SY, Zhu Z, Hu B, Homer RJ, et al. IL-13 receptor alpha2 selectively inhibits IL-13-induced responses in the murine lung. J Immunol 2008;180:522-9.
22. Kuphal S, Bosserhoff A. Recent progress in understanding the pathology of malignant melanoma. J Pathol 2009;219:400-9.
23. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, et al. SEER cancer statistics review 1975-2000. Bethesda, MD: National Cancer Institute; 2003. Tables XVI-1-9.
24. Schmidt H, Johansen JS, Gehl J, Geertsen PF, Fode K, von der Maase H. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer 2006;106:1130-9.
25. Schmidt H, Johansen JS, Sjoegren P, Christensen IJ, Sorensen BS, Fode K, et al. Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma. J Clin Oncol 2006;24:798-804.
26. Pasterkamp RJ, Peschon JJ, Spriggs MK, Kolodkin AL. Semaphorin 7A promotes axon outgrowth through integrins and MAPKs. Nature 2003;424:398-405.
27. Czopik AK, Bynoe MS, Palm N, Raine CS, Medzhitov R. Semaphorin 7A is a negative regulator of T cell responses. Immunity 2006;24:591-600.
28. Suzuki K, Kumanogoh A, Kikutani H. Semaphorins and their receptors in immune cell interactions. Nat Immunol 2008;9:17-23.
29. Lazova R, Gould Rothberg BE, Rimm D, Scott G. The semaphorin 7A receptor Plexin C1 is lost during melanoma metastasis. Am J Dermatopathol 2009;31:177-81.
30. Scott GA, McClelland LA, Fricke AF, Fender A. Plexin C1, a receptor for semaphorin 7a, inactivates cofilin and is a potential tumor suppressor for melanoma progression. J Invest Dermatol 2009;129:954-63.
31. Lee CG, Link H, Baluk P, Homer RJ, Chapoval S, Bhandari V, et al. Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. Nat Med 2004;10:1095-103.
32. Zheng T, Zhu Z, Liu W, Lee CG, Chen Q, Homer RJ, et al. Cytokine regulation of IL-13Ralpha2 and IL-13Ralpha1 in vivo and in vitro. J Allergy Clin Immunol 2003;111:720-8.
33. Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 2001;7:1118-22.
34. Donnelly ET, Kelley M, Rockwell S. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mousemammary tumor cells in vitro and in vivo. Cancer Chemother Pharmacol 2004;53:43-50.
35. Takyar S, Vasavada H, Zhang JG, Ahangari F, Niu N, Liu Q, et al. VEGF controls lung Th2 inflammation via the miR-1-Mpl (myeloproliferative leukemia virus oncogene)-P-selectin axis. J ExpMed 2013;210:1993-2010.
36. Gan Y, Reilkoff R, Peng X, Russell T, Chen Q, Mathai SK, et al. Role of semaphorin 7a signaling in transforming growth factor beta1-induced lung fibrosis and scleroderma-related interstitial lung disease. Arthritis Rheum 2011;63:2484-94.
37. Kang S, Okuno T, Takegahara N, Takamatsu H, Nojima S, Kimura T, et al. Intestinal epithelial cell-derived semaphorin 7A negatively regulates development of colitis via alphavbeta1 integrin. J Immunol 2012;188:1108-16.
38. Sohn MH, Kang MJ, Matsuura H, Bhandari V, Chen NY, Lee CG, et al. The chitinase-like proteins breast regression protein-39 and YKL-40 regulate hyperoxia-induced acute lung injury. Am J Respir Crit Care Med 2010;182:918-28.
39. Pasterkamp RJ, Kolodkin AL. Semaphorin junction: making tracks toward neural connectivity. Curr Opin Neurobiol 2003;13:79-89.
40. Nguyen DX, Massague J. Genetic determinants of cancer metastasis. Nat Rev Genet 2007;8:341-52.
41. Amatschek S, Lucas R, Eger A, Pflueger M, Hundsberger H, Knoll C, et al. CXCL9 induces chemotaxis, chemorepulsion and endothelial barrier disruption through CXCR3-mediated activation of melanoma cells. Br J Cancer 2011;104:469-79.
42. Shackleton M, Quintana E. Progress in understanding melanoma propagation. Mol Oncol 2010;4:451-7.
43. Chiang AC, Massague J. Molecular basis of metastasis. N Engl J Med 2008;359:2814-23.
44. Dougan M, Li D, Neuberg D, Mihm M, Googe P, Wong KK, et al. A dual role for the immune response in a mouse model of inflammation-associated lung cancer. J Clin Invest 2011;121:2436-46.
45. Fichtner-Feigl S, Terabe M, Kitani A, Young CA, Fuss I, Geissler EK, et al. Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2. Cancer Res 2008;68:3467-75.
46. Hebeler-Barbosa F, Rodrigues EG, Puccia R, Caires AC, Travassos LR. Gene therapy against murine melanoma B16F10-Nex2 using IL-13Ralpha2-Fc chimera and interleukin 12 in association with a cyclopalladated drug. Transl Oncol 2008;1:110-20.
47. Huang Y, Snuderl M, Jain RK. Polarization of tumor-associated macrophages: a novel strategy for vascular normalization and antitumor immunity. Cancer Cell 2011;19:1-2.
48. Nevala WK, Vachon CM, Leontovich AA, Scott CG, Thompson MA, Markovic SN. Evidence of systemic Th2-driven chronic infl ammation in patients with metastatic melanoma. Clin Cancer Res 2009;15:1931-9.
49. Scott GA, McClelland LA, Fricke AF. Semaphorin 7a promotes spreading and dendricity in human melanocytes through beta1-integrins. J Invest Dermatol 2008;128:151-61.